Benzinga

Benzinga

Benzinga

dimanche, août 23

Eupraxia Pharmaceuticals Inc

EPRXNASDAQ
Trade with Public
Trade with Public
$6.73
-0.03-0.44%
À la clôture: Aug 21, 5:00 PM EST
$6.73
N/A
Après les heures: Aug 21, 4:00 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentComparerRapport sur les stocks

Eupraxia Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Eupraxia Pharmaceuticals (EPRX).

Price Target Range — 5 Quarters

Analyst Consensus — 6 Analysts

6Buy
Consensus RatingBuy# Analysts6Avg. Consensus PT$16Upside to Avg. PT+140.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 26, 2026OppenheimerJay OlsonInitiateOutperform$17
May 21, 2026StifelAnnabel SamimyInitiateBuy$25
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17

Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.
Benzinga Newsdesk

This SailPoint Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Top analysts changed outlook on top names. See all rating changes at benzinga.com/analyst-stock-ratings. Considering SAIL stock? Here's what analysts say.
Avi Kapoor

PRO
Stifel Initiates Coverage On Eupraxia Pharmaceuticals with Buy Rating, Announces Price Target of $25

Stifel analyst Annabel Samimy initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy rating and announces Price Target of $25.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $11 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $11 price target.
Benzinga Newsdesk

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.
Vandana Singh

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved